US007914815B2

(12) **United States Patent**
**Till et al.**

(10) **Patent No.: US 7,914,815 B2**
(45) **Date of Patent: *Mar. 29, 2011**

(54) **METHOD FOR DELIVERY OF PHARMACEUTICALS FOR TREATING OR PREVENTING PRESBYOPIA**

(75) Inventors: **Jonathan S. Till**, Salem, VA (US); **Ronald D. Blum**, Roanoke, VA (US); **William Kokonaski**, Gig Harbor, WA (US); **Dwight P. Duston**, Laguna Niguel, CA (US)

(73) Assignee: **Encore Health, LLC**, Roanoke, VA (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1662 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **11/135,271**

(22) Filed: **May 24, 2005**

(65) **Prior Publication Data**

US 2005/0287201 A1 Dec. 29, 2005

**Related U.S. Application Data**

(63) Continuation-in-part of application No. 10/050,879, filed on Jan. 18, 2002, now Pat. No. 6,923,955, which is a continuation-in-part of application No. 09/930,287, filed on Aug. 16, 2001, now abandoned.

(60) Provisional application No. 60/574,211, filed on May 26, 2004, provisional application No. 60/262,423, filed on Jan. 19, 2001, provisional application No. 60/225,659, filed on Aug. 16, 2000.

(51) **Int. Cl.**
*A61F 2/14* (2006.01)
*A61K 9/127* (2006.01)

(52) **U.S. Cl.** ..... **424/450**; 604/20

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 3,238,224 | A | 3/1966 | Ohara et al. |
| 3,855,240 | A | 12/1974 | Mueller |
| 4,210,667 | A | 7/1980 | Sarges et al. |
| 4,755,528 | A | 7/1988 | DuPriest et al. |
| 5,395,356 | A | 3/1995 | King et al. |
| 5,459,133 | A | 10/1995 | Neufeild |
| 5,465,737 | A | 11/1995 | Schachar |
| 5,466,680 | A | 11/1995 | Rudy |
| 5,476,515 | A | 12/1995 | Kelman |
| 5,488,050 | A | 1/1996 | Neufeld |
| 5,503,165 | A | 4/1996 | Schachar |
| 5,527,774 | A | 6/1996 | Girard |
| 5,529,076 | A | 6/1996 | Schachar |
| 5,624,955 | A | 4/1997 | Nagasawa et al. |
| 5,665,770 | A | 9/1997 | Terao et al. |
| 5,686,450 | A | 11/1997 | Hellberg et al. |
| 5,688,828 | A | 11/1997 | Hellberg et al. |
| 5,691,379 | A | 11/1997 | Ulrich et al. |
| 5,722,952 | A | 3/1998 | Schachar |
| 5,817,630 | A | 10/1998 | Hoffmann et al. |
| 5,843,184 | A | 12/1998 | Cionni |
| 5,869,468 | A | 2/1999 | Freeman |
| 5,874,455 | A | 2/1999 | Terao et al. |
| 5,888,243 | A | 3/1999 | Silverstrini |
| 6,007,510 | A | 12/1999 | Nigam |
| 6,013,462 | A | 1/2000 | Kauvar et al. |
| 6,030,950 | A | 2/2000 | Ohlenschlager |
| 6,063,116 | A * | 5/2000 | Kelleher ..... 623/6.56 |
| 6,214,044 | B1 | 4/2001 | Silverstrini |
| 6,313,164 | B1 | 11/2001 | Fujita et al. |
| 6,339,102 | B1 | 1/2002 | Meyerhoff et al. |
| 6,387,945 | B2 | 5/2002 | Packer et al. |
| 6,472,541 | B2 | 10/2002 | Tsien et al. |
| 6,664,287 | B2 | 12/2003 | Avery et al. |
| 6,703,039 | B2 | 3/2004 | Xia et al. |
| 6,743,779 | B1 * | 6/2004 | Unger et al. ..... 514/44 |
| 6,923,955 | B2 | 8/2005 | Till et al. |
| 7,164,943 | B2 | 1/2007 | Roy |
| 2002/0035243 | A1 | 3/2002 | Imfeld et al. |
| 2003/0187058 | A1 | 10/2003 | Hasselwander et al. |
| 2003/0228299 | A1 | 12/2003 | Droy-Lefaix et al. |
| 2004/0044227 | A1 | 3/2004 | Klatt et al. |
| 2004/0092586 | A1 | 5/2004 | Ogata et al. |
| 2005/0101677 | A1 | 5/2005 | Till |
| 2005/0112113 | A1 | 5/2005 | Till et al. |
| 2005/0130881 | A1 | 6/2005 | Shashoua et al. |
| 2005/0137124 | A1 | 6/2005 | Castillejos |
| 2005/0171212 | A1 | 8/2005 | Gierhart et al. |

(Continued)

FOREIGN PATENT DOCUMENTS

| | | |
|---|---|---|
| EP | 0 369 880 | 5/1990 |

(Continued)

OTHER PUBLICATIONS

Bron, A.J., et al. "The Ageing Lens" Ophthalmologica (2000) 214(1):86-104.

(Continued)

*Primary Examiner* — Shanon A Foley

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend Stockton LLP

(57) **ABSTRACT**

Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens fibers of the lens of the eye. Methods include iontophoresis, nano-medication, and photonic activation to deliver the pharmaceuticals to treat or prevent presbyopia.

**17 Claims, 2 Drawing Sheets**